ClinicalTrials.gg

Program

KNT-0916

A development code.

Its studies are led by KinoTeck Therapeutics.

Furthest: phase 1, since Jan 20, 20251 company-led study, 1 open or runningNext primary completion: Sep 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
KinoTeck Therapeutics11 open or runningphase 1since Jan 20, 2025Jan 20, 2025Sep 30, 2027phase 1 · NCT06800196

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 20, 2025First study: phase 1 study in Solid Tumors With FGFR2 Alterations, AdultFirst studyNCT06800196 · 151 planned · China

Ahead

  1. Sep 30, 2027Primary completion: phase 1 study in Solid Tumors With FGFR2 Alterations, AdultNCT06800196

TargetBeta

FGFR2 →read by rule
“• KNT-0916 is an oral inhibitor of FGFR2.”study text, by rule · the study

Other programs on FGFR2

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
infigratinibruleBridgeBiophase 317
pemigatinibruleIncytephase 316
futibatinibruleOtsukaphase 310
lirafugratinibruleelevar-therapeuticsphase 22
FGFR2/3 Inhibitor CGT4859rulecogent-biosciences-incphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06800196Solid Tumors With FGFR2 Alterations, Adult · China1RecruitingSep 30, 2027151

How it is read

Names in the registry

  • “KNT-0916”, 1 entry

Codes read as this program: KNT0916.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.